INS and Alzheimer disease: Thus, in the early stages, AD is marked by deficits in cerebral glucose utilization and energy metabolism, and as AD progresses, impairments in insulin signaling, insulin-responsive gene expression, glucose utilization, and metabolism worsen [85,117,118,119,120,121,122,123,124].